Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $43.65 million. The enterprise value is -$23.25 million.

Market Cap	43.65M
Enterprise Value	-23.25M

Important Dates

The last earnings date was Tuesday, May 7, 2024, after market close.

Earnings Date	May 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 29.65 million shares outstanding. The number of shares has increased by 11.07% in one year.

Shares Outstanding	29.65M
Shares Change (YoY)	+11.07%
Shares Change (QoQ)	+0.31%
Owned by Insiders (%)	29.15%
Owned by Institutions (%)	34.91%
Float	17.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.55
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 14.38, with a Debt / Equity ratio of 0.06.

Current Ratio	14.38
Quick Ratio	n/a
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -55.80% and return on invested capital (ROIC) is -71.07%.

Return on Equity (ROE)	-55.80%
Return on Assets (ROA)	-50.50%
Return on Capital (ROIC)	-71.07%
Revenue Per Employee	n/a
Profits Per Employee	-$833,466
Employee Count	65
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -83.03% in the last 52 weeks. The beta is -0.60, so Immuneering's price volatility has been lower than the market average.

Beta (1Y)	-0.60
52-Week Price Change	-83.03%
50-Day Moving Average	2.31
200-Day Moving Average	5.92
Relative Strength Index (RSI)	34.26
Average Volume (30 Days)	781,570

Short Selling Information

The latest short interest is 3.21 million, so 10.82% of the outstanding shares have been sold short.

Short Interest	3.21M
Short Previous Month	2.73M
Short % of Shares Out	10.82%
Short % of Float	18.43%
Short Ratio (days to cover)	5.70

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-59.06M
Pretax Income	-54.18M
Net Income	-54.18M
EBITDA	-53.41M
EBIT	-54.18M
Earnings Per Share (EPS)	-$1.87

Full Income Statement

Balance Sheet

The company has $71.28 million in cash and $4.38 million in debt, giving a net cash position of $66.90 million or $2.26 per share.

Cash & Cash Equivalents	71.28M
Total Debt	4.38M
Net Cash	66.90M
Net Cash Per Share	$2.26
Equity / Book Value	78.72M
Book Value Per Share	2.65
Working Capital	69.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$50.04 million and capital expenditures -$352,231, giving a free cash flow of -$50.39 million.

Operating Cash Flow	-50.04M
Capital Expenditures	-352,231
Free Cash Flow	-50.39M
FCF Per Share	-$1.72

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.07%
Shareholder Yield	-11.07%
Earnings Yield	-124.11%
FCF Yield	-115.45%

Analyst Forecast

The average price target for Immuneering is $15.14, which is 929.93% higher than the current price. The consensus rating is "Buy".

Price Target	$15.14
Price Target Difference	929.93%
Analyst Consensus	Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-5.99%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2